Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.48 |
| ▸ | GRM5 | P41594 | 8/20 | 0.48 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30913581 | 0.89 | PDK4 (0.51) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL25167744 | 0.89 | PDK4 (0.51) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL31444234 | 0.87 | PDK4 (0.51) | NAMPTPDK4GRM1GRM5CNR1 | |
| SCHEMBL30952401 | 0.86 | NAMPT (0.47) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL24319286 | 0.85 | GRM1 (0.47) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL23120751 | 0.83 | DDB1 (0.52) | CNR1DDB1CRBN | |
| SCHEMBL22324903 | 0.82 | NAMPT (0.53) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL31201927 | 0.82 | PDK4 (0.46) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL29223732 | 0.82 | PDK4 (0.46) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL31323741 | 0.81 | NAMPT (0.45) | NAMPTPDK4GRM1GRM5CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | NAMPT 2821/4885PDK4 2531/4885GRM1 4485/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | NAMPT 574/4885PDK4 163/4885GRM1 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.